This technology is a targeted anti-tumor agent designed to treat adenoid cystic carcinoma (ACC) by utilizing retinoid receptor modulation to promote cancer cell differentiation and selective cell death.
Adenoid cystic carcinoma (ACC) is an aggressive cancer of the salivary glands. ACCs often metastasize, and 60% of patients affected die within 15 years of their initial diagnosis. There are currently no FDA-approved systemic or targeted therapies for treating ACC.
This technology employs both direct and inverse agonists of retinoic acid receptor (RAR) and retinoid X receptor (RXR) signaling to modify the composition of adenoid cystic carcinoma (ACC) tumors, causing aggressive myoepithelial-like cells to differentiate into less tumorigenic ductal-like cells. These ductal-like cells can then be killed using inverse agonists of RAR/RXR signaling, with or without other forms of treatment.
This technology has been validated with patient-derived human cancer cell lines and three-dimensional organoids.
Patent Issued (US 12,115,140)
IR CU20036, CU21018, CU21357, CU23276
Licensing Contact: Kristin Neuman